Impel NeuroPharma Inc. (IMPL) said that the U.S. Food and Drug Administration approved Trudhesa or dihydroergotamine mesylate nasal spray (0.725 mg per spray) for the acute treatment of migraine with or without aura in adults. It will be commercially available in early October 2021.
In Friday regular trading, IMPL was trading at $30.98 up $7.86 or 34.00%.
The company noted that Trudhesa will be available through Trudhesa Direct, a hassle-free pharmacy partnership and copay program. The digital pharmacy fulfilment partners, Phil Inc. and Carepoint Pharmacy, will provide electronic prescribing and automatic enrollment in the patient savings program for eligible, commercially insured patients without the need for a paper copay card.
For comments and feedback contact: editorial@rttnews.com
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.